Cambridge, United States
Laronde, founded in 2017 by Flagship Labs, is at the forefront of biotechnology innovation with its pioneering Endless RNA™ (eRNA) platform. Differentiated by its ability to modulate human biology, this uniquely engineered RNA can be programmed to express a variety of proteins within the body. Its persistent and non-immunogenic features, along with repeat dosing capabilities and formulation flexibility, position Laronde as a game-changer in Health and Wellness and Biotechnology sectors.
The company, headquartered in the United States, is experiencing rapid scaling to facilitate simultaneous program developments across several disease areas. A substantial $440.00M Series B investment on August 30, 2021, backed by prominent investors like CPP Investments, BlackRock, and Fidelity, underscores investor confidence in its innovative potential. As Laronde continues to advance, it stands as a significant contender in biotechnological therapeutic solutions.
